Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04074421
Other study ID # (2019) Study No. 413
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date May 10, 2020
Est. completion date December 2022

Study information

Verified date August 2019
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Liangjing Wang, Ph.D
Phone +8613777848083
Email wangljzju@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on different symptoms and quality of life. High-throughput sequencing combined with real-time quantitative PCR will be used to comprehensively analyze the effects of different drugs on intestinal flora. The study has important guiding significance for the treatment of patients with IBS-D.


Description:

According to the Rome IV diagnostic criteria, 200 patients with with diarrhoea-predominant irritable bowel syndrome (IBS-D) from the multi-center (8 units in the country) will be enrolled. The IBS Severity Inventory (IBS-SSS) and IBS Quality of Life Scores (QOL) will be used to evaluate the effect of treatments. Retreatment patients who are initially treated and not satisfied with the improvement of symptoms and quality of life will be treated with Rifaximin for 2 weeks. Fecal specimens will be collected from patients who responded to treatment, and the fecal bacteria will be analyzed by real-time polymerase chain reaction (PCR) using 16 S ribosomal ribonucleic acid (rRNA) gene. Patients who responded to Rifaximin treatment will be randomized into A (Probiotics group) and B (Placebo group). IBS symptom grade score and quality of life score will be evaluated before and after treatment, and fecal specimens of the responding patients will be collected for intestinal probiotics and harmful bacteria detection.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date December 2022
Est. primary completion date June 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- 18-75 years old;

- in line with the diagnostic criteria of diarrhea-type irritable bowel syndrome Roman IV;

- blood routine, blood biochemistry, stool examination and colonoscopy within 2 years are no problem;

- no intestinal warning symptoms

Exclusion Criteria:

- suffering from severe heart, lung, liver, kidney, nervous system diseases;

- suffering from mental disorders caused by schizophrenia, brain organic and physical diseases;

- suffering from other diseases that may affect intestinal function (such as diabetes, thyroid disease);

- History of previous abdominal surgery (excluding history of cholecystectomy or appendectomy);

- pregnant or lactating women;

- have undergone colonoscopy in the past month or accept other bowel preparation operations;

- In the past 1 month, have used antibiotics, antidiarrheal agents, intestinal flora regulation, Chinese medicine and other drugs;

- have participated in other dietary treatments;

- understand communication barriers, unable to communicate

Study Design


Intervention

Drug:
Rifaximin
A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.
Probiotic Formula
A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.
Placebo oral tablet
Placebo oral tablet that has no therapeutic effect

Locations

Country Name City State
China The Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang

Sponsors (7)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University First Affiliated Hospital of Wenzhou Medical University, Peking Union Medical College Hospital, RenJi Hospital, Sir Run Run Shaw Hospital, The Central Hospital of Lishui City, The First Affiliated Hospital of Zhejiang Chinese Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the IBS symptom grade score The IBS Severity Inventory (IBS-SSS) will be used to evaluate the IBS symptom grade score The IBS Severity Inventory (IBS-SSS) will be used to evaluate the IBS symptom grade score baseline
Primary the quality of life score IBS Quality of Life Scores (QOL) will be used to evaluate the quality of life score baseline
Primary the IBS symptom grade score The IBS Severity Inventory (IBS-SSS) will be used to evaluate the IBS symptom grade score The IBS Severity Inventory (IBS-SSS) will be used to evaluate the IBS symptom grade score 2 weeks
Primary the quality of life score IBS Quality of Life Scores (QOL) will be used to evaluate the quality of life score 2 weeks
Primary the IBS symptom grade score The IBS Severity Inventory (IBS-SSS) will be used to evaluate the IBS symptom grade score 12 weeks
Primary the quality of life score IBS Quality of Life Scores (QOL) will be used to evaluate the quality of life score 12 weeks
Primary 16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota 16 S rRNA (ribosomal ribonucleic acid) sequencing will be applied to determine the change of microbial community 12 weeks
Primary 16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota 16 S rRNA (ribosomal ribonucleic acid) sequencing will be applied to determine the change of microbial community baseline
Primary 16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota 16 S rRNA (ribosomal ribonucleic acid) sequencing will be applied to determine the change of microbial community 2 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04991792 - Effect of an Infant Formula With Synbiotics in Infants Born Via Caesarean Section N/A
Completed NCT02151825 - Effect of a Synbiotic on the Gut Microbiota and Adiposity-related Markers in Healthy Overweight Subjects N/A
Completed NCT01545219 - A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers N/A
Active, not recruiting NCT04435548 - Westlake Gut Microbiome Study
Enrolling by invitation NCT05057039 - The Study of Gut Microbiota in Hypertensive Patients
Not yet recruiting NCT05039060 - Modified MAC Diet and Gut Microbiota in CRC Patients N/A
Completed NCT03746158 - Interindividual Variation in Excretion of Curcumin N/A
Active, not recruiting NCT03266055 - Effects of Blueberry on Gut Microbiota and Metabolic Syndrome N/A
Completed NCT04960878 - The Effect of Synbiotics on the Upper Respiratory Tract Infection N/A
Active, not recruiting NCT05607745 - Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study N/A
Recruiting NCT04120051 - The SIMBA Project - The Effect of a Prebiotic Supplement on Glucose Metabolism and Gut Microbiota in Obese Adults N/A
Not yet recruiting NCT05481866 - Targeting Gut Microbiota and Metabolites for Very Preterm Infants Through Oropharyngeal Administration of Colostrum N/A
Completed NCT03293693 - Intake of Beta-glucan and Postprandial Regulation of Blood Glucose Metabolism in Healthy Subjects N/A
Completed NCT02207140 - Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly Phase 0
Recruiting NCT04203459 - The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation
Active, not recruiting NCT03259685 - Effect of Non-nutritive Sweeteners of High Sugar Sweetened Beverages on Metabolic Health and Gut Microbiome N/A
Recruiting NCT06157346 - Characteristics of Intestinal Bacteria and Their Effects on Growth and Immune Function in Children at High Altitude
Completed NCT03203044 - Impact of Soylent Consumption on Human Microbiome Composition N/A
Recruiting NCT05975541 - Susceptibility to Infectious Diseases in Obesity
Active, not recruiting NCT05457439 - Sustainable-psycho-nutritional Intervention Program and Its Effects on Health Outcomes and the Environment N/A